Inhibition of LDL oxidation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)

Atherosclerosis

Volumn 126, Issue 1, 1996, Pages 65-75

  Zuckerman, Steven H ^a   Bryan, Nancy ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Lipoperoxides; Low density lipoproteins; Macrophages; Oxidation; Phagocytosis

Indexed keywords

DEXAMETHASONE; ESTRADIOL; ESTROGEN RECEPTOR; HORSERADISH PEROXIDASE; LOW DENSITY LIPOPROTEIN; MYELOPEROXIDASE; RALOXIFENE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; IN VITRO STUDY; LIPID PEROXIDATION; MACROPHAGE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL;

EID: 0030604022     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/0021-9150(96)05894-7     Document Type: Article

References (50)

1. [1] Ross R. Cell biology of atherosclerosis. Annu Rev Physiol 1995;57:791.
2. [2] Daugherty A, Roselaar SE. Lipoprotein oxidation as a mediator of atherogenesis: insights from pharmacological studies. Cardiovasc Res 1995;29:297.
3. [3] Walsh RW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of post-menopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196.
4. [4] Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekes CH. Post-menopausal estrogen therapy and cardiovascular disease: 10-year follow-up from the nurse's health study. N Engl J Med 1991;325:756.
5. [5] Schaefer EJ, Foster DM, Zech LA, Lindgren FT, Brewer HB, Levy RI. The effects of estrogen administration on plasma lipoprotein metabolism in pre-menopausal females. J Clin Endocrinol Metab 1983;57:262.
6. [6] Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106.
7. [7] Gaziano JM, Manson JE, Buring JE, Hennekes CH. Dietary anti-oxidants and cardiovascular disease. Ann NY Acad Sci 1992;669:249.
8. [8] Gey KF, Puska P. Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology. Ann NY Acad Sci 1989;570:268.
9. [9] Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 1989;98:612.
10. [10] Carew TE, Schwenke DC, Steinberg D. Anti-atherogenic effects of probucol unrelated to its hypocholesterolemic effect: evidence that anti-oxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725.
11. [11] Jansson G. Oestrogen-induced enhancement of myeloperoxidase activity in human PMN leukocytes; a possible cause of oxidative stress in inflammatory cells. Free Rad Res Comm 1991;14:195.
12. [12] Huber LA, Scheffler E, Poll KT, Ziegler R, Dresel HA. 17β-estradiol inhibits LDL oxidation and cholesteryl ester formation in cultured macrophages. Free Rad Res Comm 1990;8:167.
13. [13] Maziere C, Auclair M, Ronveaux M-F, Salmon S, Santus R, Maziere J-C. Estrogens inhibit copper and cell-mediated modification of low density lipoprotein. Atherosclerosis 1991;89:175.
14. [14] Subbiah MTR, Kessel B, Agrawal M, Rajan R, Abplanalp W, Rymaszewski Z. Anti-oxidant potential of specific estrogens on lipid peroxidation. J Clin Endocrinol Metab 1993:77:1095.
15. [15] Lacort M, Leal AM, Liza M, Martin C, Martinez R, Ruiz-Larrea MB. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids 1995;30:141.
16. [16] Esterbauer H, Gebicki J, Puhl H, Jurgens G. The role of lipid peroxidation and anti-oxidants in oxidative modification of LDL. Free Rad Biol Med 1992;13:341.
17. [17] Keaney JF, Shwaery GT, Xu A, Nicolosi RJ, Loscalzo, J, Foxall TL, Vita JA. 17β-estradiol preserves endothelial vasodilator function and limits low-density lipoprotein oxidation in hypercholesterolemic swine. Circulation 1994;89:2251.
18. [18] Black LJ, Sato M, Rowley ER, Magee DE, Bekele KA, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR, Frolik C, Termine J, Bryant HU. Raloxifene (LY139481 HCL) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63.
19. [19] Draper MW, Flowers DE, Huster WJ, Neild JA. Effects of raloxifene (LY139481 HCL) on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. 1993;119 (Abstract). Proc 4th Int. Symp. Osteoporosis, Hong Kong.
20. [20] Puhl H, Waeg G, Esterbauer H. Methods to determine oxidation of low density lipoproteins. Methods Enzymol 1994;233:425.
21. [21] Ragsdale RL, Grasso RJ. An improved spectrofluorometric assay for quantitating yeast phagocytosis in cultures of murine peritoneal macrophages. J lmmunol Meth 1989;123:259.
22. [22] Amado R, Aeschbach R, Neukom H. Dityrosine: In vitro production and characterization. Methods Enzymol 1984;107:377.
23. [23] Francis GA, Mendez AJ, Bierman EL, Heinecke JW. Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc Natl Acad Sci USA 1993;90:6631.
24. [24] Heinecke JW, Li W, Francis GA, Goldstein JA. Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 1993;91:2866.
25. [25] Quinn MT, Parthasarathy S, Fong LG, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/ macrophages during atherogenesis. Proc Natl Acad Sci USA 1987;84:2995.
26. [26] Cushing SD, Berliner JA, Territo MC, Valante AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein-1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA 1990;87:5134.
27. [27] Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA. Minimally oxidized low density lipoprotein induces tissue factor expression in cultured human endothelial cells. Am J Pathol 1991;138:601.
28. [28] Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 1992;90:1138.
29. [29] Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Ann Rev Biochem 1983;52:223.
30. [30] Cathcart MK, Morel DW, Chisolm GM. Monocytes and neutrophils oxidize low density lipoprotein, making it cytotoxic. J Leukocyte Biol 1985;38:341.
31. [31] Heinecke JW, Baker L, Rosen H, Chait A. Superoxide mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest 1986;77:757.
32. [32] Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984;81:3883.
33. [33] Kuhn H, Belkner J, Zaiss S, Fahrenklemper T, Wohnfeil S. Involvement of 15-lipoxygenase in early stages of atherogenesis. J Exp Med 1994;179:1903.
34. [34] Sparrow CP, Olszewski J. Cellular oxidative modifications of low density lipoprotein does not require lipoxygenases. Proc Natl Acad Sci USA 1992;89:128.
35. [35] Santanam N, Parthasarathy S. Paradoxical actions of anti-oxidants in the oxidation of low density lipoprotein by peroxidases. J Clin Invest 1995;95:2594.
36. [36] Savenkova MI, Mueller DM, Heinecke JW. Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for the initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994;269:20394.
37. [37] Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Glass CK, Sigal E, Witztum JL, Steinberg D. Co-localization of 15-lipoxygenase messenger RNA and protein epitopes of oxidized low density lipoprotein in macrophage rich areas of atherosclerotic lesions. Proc Natl Acad Sci USA 1990;87:6959.
38. [38] Mowri H, Ohkuma S, Takano T. DLR1a/104G antibody recognizing peroxidized lipoproteins in atherosclerotic lesions. Biochim Biophys Acta 1988;963:208.
39. [39] Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989;84:1086.
40. [40] Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL. Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 1990;10:336.
41. [41] Egan RW, Hagmann WK, Gale PH. Napthalenes as inhibitors of myeloperoxidase: direct and indirect mechanisms of inhibition. Agents Action 1990;29:265.
42. 2-receptor antagonists. Effects on myeloperoxidase-catalysed reactions and hydroxyl radical generation in a ferrous-hydrogen peroxide system. Biochem Pharmacol 1993;45:2389.
43. [43] Kettle AJ, Winterbourn CC. Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs. Biochem Pharmacol 1991;41:1485.
44. [44] Zuurbier KWM, Bakkenist ARJ, Fokkens RH, Nibbering NMM, Wever R, Muijsers AO. Interaction of myeloperoxidase with diclofenac. Inhibition of the chlorinating activity of myeloperoxidase by diclofenac and oxidation of diclofenac to dihydroxyazobenzene by myeloperoxidase. Biochem Pharmacol 1990;40:1801.
45. [45] Giroux LM, Davignon J, Naruszewicz M. Simvastatin inhibits the oxidation of low density lipoproteins by activated human monocyte-derived macrophages. Biochim Biophys Acta 1993;1165:335.
46. [46] Yue T-L, McKenna PJ, Lysko PG, Ruffolo RR, Feuerstein GZ. Carvedilol, a new anti-hypertensive, prevents oxidation of human low density lipoprotein by macrophages and copper. Atherosclerosis 1992;97:209.
47. [47] Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 1989;98:612.
48. [48] Carew TE, Schwenke DC, Steinberg D. Anti-atherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that anti-oxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987;84:7725.
49. [49] Carr, BR. Disorders of the ovary and female reproductive tract. In: Wilson JD and Foster DW (eds). Williams Textbook of Endocrinology. Eighth Edition. Philadelphia, PA: W.B. Saunders Co., 1992;733.
50. [50] Daugherty A, Dunn JL, Rateri RL, Heinecke JW. Myeloperoxidase, a catalyst for lipoprotein oxidation is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437.